DRAMMATIC
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
What will happen during the trial?
Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 1,100 patients (estimated)
- Sponsors
- Southwest Oncology Group
- Collaborators
- National Cancer Institute (NCI), Janssen Research & Development LLC
- Tags
- Monoclonal Antibody, CD38, Maintenance, Post-Autologous Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1019
- NCT Identifier
- NCT04071457
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.